Compound ID | 48

Update compound information

SASPject3.1

Class: Bacteriophage and/or bacteriophage-derived product

Agent Type: Bacteriophage or bacteriphage-derived product;
Spectrum of activity: Gram-negative
Mechanism of action: Utilises small acid soluble spore proteins which bind to DNA
Target Pathogen: Active against Pseudomonas aeruginosa
Propensity to select resistant mutants: Yes
Description: Delivered by bacteriophage
Institute where first reported: Phico Therapeutics Ltd., UK
Year first mentioned: 2014
Highest developmental phase: Preclinical
Development status: Experimental
External links:
Citations:
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538823/
  • http://www.phicotx.co.uk/#products
  • https://carb-x.org/carb-x-news/carb-x-is-funding-phico-therapeutics-to-develop-an-engineered-bacteriophage-drug-to-treat-ventilator-associated-pneumonia-caused-by-drug-resistant-pseudomonas-aeruginosa/
    • Patent: US20140242032A1

    AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.